All In Biotech

Drug Trial Radar · NCT04894994

FLX475 in Combination With Ipilimumab in Advanced Melanoma

Phase 2 Study of FLX475 in Combination With Ipilimumab in Advanced Melanoma

Last checked: Nov 19, 2026Latest source record: Dec 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

6

Actual

Start

Sep 3, 2021

Primary completion

Sep 13, 2022

Study completion Sep 13, 2022

Sponsor

Sponsor type
Industry
First posted
May 20, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial is a Phase 2, open-label study to determine the anti-tumor activity of FLX475 in combination with ipilimumab in subjects with advanced melanoma previously treated with an anti-programmed cell death 1 (anti-PD-1) or anti-programmed cell death ligand 1 (anti-PD-L1) agent. The study will be conducted starting with a safety run-in portion in which 6 eligible subjects will be enrolled and treated for at least one 3-week cycle to determine if the safety profile of FLX475+ipilimumab is acceptable to complete enrollment of the approximately 20-subject study.

Conditions

  • Advanced Melanoma

Interventions

  • FLX475Drug

    Tablet

  • IpilimumabDrug

    IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response RateTime frame: Approximately 1 year
  2. Safety and Tolerability as Measured by Number of Participants That Experienced Other Adverse EventsTime frame: Approximately 3 weeks
  3. Safety and Tolerability as Measured by Number of Participants That Experienced Serious Adverse EventsTime frame: Approximately 3 weeks

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of California, Los Angeles

    Los Angeles, California

  • Moffitt Cancer Center

    Tampa, Florida

  • Washington University School of Medicine St. Louis

    St Louis, Missouri

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.